Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer - A Multicenter Single Arm Phase II Trial

NCT02833766 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT02833766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02833766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer - A Multicenter Single Arm Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Terminated
Start date
October 28, 2016
Completion date
August 3, 2021
Enrollment
48 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer